Research continues on how this pairing may influence fat metabolism and endurance
European Medicines Agency (EMA): The European Unions EMA oversees the safety of medicines
Currently, most insurance coverage for GLP-1 RAs is limited to patients with type 2 diabetes, although their use for cardiovascular risk reduction in non-diabetic patients continues to gain support from clinical evidence [21]
Kishimoto S, Kinoshita Y, Matsumoto T, Maruhashi T, Kajikawa M, Matsui S, Hashimoto H, Takaeko Y, Kihara Y, Chayama K, Goto C, Mohamad Yusoff F, Nakashima A, Noma K, Higashi Y (2019) Effects of the dipeptidyl peptidase 4 inhibitor alogliptin on blood pressure in hypertensive patients with type 2 diabetes mellitus
It is particularly beneficial to patients with CFS (chronic fatigue syndrome), reducing the severity of symptoms
Vanessa Mack is committed to helping you achieve and maintain your weight loss goals through a combination of lifestyle changes and ongoing medical support